

BEST AVAILABLE COPY

Docket No.: 49,632 (71699)

#7
4/15/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Pamela L. Zeitlin, et al. EXAMINER: Wang, S.
SERIAL NO.: 09/523,776 GROUP: 1617
FILED: March 11, 2000
FOR: MODULATION OF PROTEIN EXPRESSION USING CARBOCYCLIC
ARYL ALKENOIC ACID DERIVATIVES

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: August 30, 2001By: Patricia A. Barnes
Patricia A. Barnes*****
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

RESPONSE TO RESTRICTION REQUIREMENT

In response to the Office action mailed June 5, 2001, Applicants provisionally elect Group I, i.e., Claims 15, 16 and 24 drawn to a method for treatment of cystic fibrosis, with traverse. Further elected with traverse is the compound 4-phenyl-Δ³-transbutenoic acid to satisfy the species election requirement.

REMARKS

Applicants respectfully request reconsideration of the Restriction Requirement.